Multi-omics biomarkers in endometrial receptivity: from mechanisms to clinical translation Authors: Xingtong Chen, Penghui Feng, Jinming Zhang, Jiaming Wu, Zhuolin Xie, Jingbo Huang, Xuanjin Yang, Falin He, Rong Chen Published: 2026 ABSTRACT BackgroundEndometrial receptivity (ER) serves as a critical determinant for successful embryo implantation, yet its molecular complexity and limited clinical assessment methods pose significant challenges. Despite advancements in assisted reproductive technology (ART), recurrent implantation failure (RIF) linked to ER abnormalities persists, creating a need for precise, non-invasive diagnostics.Main bodyThis review outlines ER research, from the biology of the window of implantation (WOI) to the roles of immune components and the microbiome in shaping the receptive microenvironment. Multi-omics integration reveals regulatory networks across transcriptomic, epigenomic, proteomic, and metabolomic levels, with uterine fluid biomarkers emerging as promising non-invasive candidates. The analysis further covers how chronic endometritis (CE), adenomyosis, and polycystic ovary syndrome (PCOS) impair ER: through mechanisms including inflammatory imbalance, microbial dysbiosis, abnormal extracellular matrix remodeling, and hormonal dysregulation. Commercial ER tests face limitations, including insufficient evidence and inconsistent results, which undermine their clinical reliability.ConclusionsA significant translational gap remains between biomarker discovery and clinical application. Current challenges involve technical standardization and data integration, and poor model generalizability. Future progress requires combining multi-omics with artificial intelligence (AI) to establish standardized clinical pathways, advancing ER assessment into precision medicine, and improving global infertility management. Introduction Endometrial receptivity (ER) refers to the ability of the endometrium to accept and support embryo implantation, which is crucial for successful pregnancy. A receptive endometrium undergoes complex biological processes such as decidualization, tissue remodeling, immune regulation, and angiogenesis. These hormone-regulated events occur during a specific time window—the “window of implantation” (WOI)—when the endometrium reaches a functional state to support embryo adhesion and invasion [1, 2, 3]. It is estimated that embryonic factors account for approximately one-third of recurrent implantation failure (RIF) cases, while ER defects and abnormal endometrial-embryo interactions constitute about two-thirds. Globally, over 10 million babies have been born through ART, accounting for 7.9% and 5.1% of newborns in Europe and the United States, respectively [4, 5]. Currently, there is no completely unified definition for RIF. Previous definitions have largely been based on the number of failed cycles, the number of embryos transferred, or a combination of both [6–10]. With advances in ART and single-embryo transfer, the definition of RIF has evolved from simple criteria based on the number of failed cycles to more personalized approaches that consider the expected implantation rate based on patient and embryo characteristics. [11]. In 2023, the European Society of Human Reproduction and Embryology (ESHRE) proposed a more personalized definition: RIF is indicated when the cumulative implantation success rate falls below 60% of the rate predicted by a mathematical model, underscoring the need for individualized diagnosis and intervention [11]. The lack of a unified definition introduces heterogeneity that complicates cross-study comparisons and meta-analyses of biomarker data. This variability—encompassing the number of failed cycles (typically 2–3), embryo quality thresholds, and maternal age—must be accounted for when evaluating biomarker panel performance. Meanwhile, there is no gold standard for assessing ER or WOI. In clinical practice, traditional methods such as ultrasound, hysteroscopy, and endometrial biopsy are commonly used to determine WOI timing [6, 12]. However, these methods have inherent limitations [6, 13, 14]. Ultrasound is widely used due to its non-invasive nature, real-time monitoring capability, and established technology, but it remains cost-intensive. Endometrial biopsy provides critical information about ER status but suffers from invasiveness and timing constraints that restrict clinical application [15, 16]. Researchers are increasingly focusing on analyzing biomarkers in body fluids, particularly miRNAs and related proteins in blood and uterine cavity fluid, to develop more effective evaluation tools [17, 18]. Therefore, there is an urgent clinical need for rapid and cost-effective biomarkers to address the limitations of current assessment tools. This review synthesizes recent advances in identifying high-potential, low-cost ER biomarkers and proposes novel evaluation strategies for populations with suspected RIF (Fig. 1). We categorize the key ER biomarkers into several research areas—transcriptomic, epigenetic, proteomics, and metabolomics—with dedicated discussions of immune-related markers, microbiome characteristics, and commercially available diagnostic platforms (Fig. 2). This framework bridges mechanistic insights with clinical applications, offering actionable solutions for precision embryo transfer (ET) in ART.Fig. 1Overview of biomarkers for ER. The figure illustrates the evolution of ER biomarkers from 1975 onward. Highlights key discoveries from tissue biopsy to exosomal analysis, shaping our understanding of this reproductive processFig. 2Integrated network of multi-omics biomarkers for ER. This diagram illustrates the major biomarker categories and their interactions in ER. The left panel describes multi-dimensional omics, which include transcriptome, epigenome, microbiome, metabolome, and proteome. The middle panel illustrates collectively core functional processes: embryo adhesion, endometrial remodeling and decidualization, angiogenesis and vascular remodeling, and immune tolerance. The right panel further demonstrates clinical diagnostic tools Overview of biomarkers for ER. The figure illustrates the evolution of ER biomarkers from 1975 onward. Highlights key discoveries from tissue biopsy to exosomal analysis, shaping our understanding of this reproductive process Integrated network of multi-omics biomarkers for ER. This diagram illustrates the major biomarker categories and their interactions in ER. The left panel describes multi-dimensional omics, which include transcriptome, epigenome, microbiome, metabolome, and proteome. The middle panel illustrates collectively core functional processes: embryo adhesion, endometrial remodeling and decidualization, angiogenesis and vascular remodeling, and immune tolerance. The right panel further demonstrates clinical diagnostic tools Biological basis and cellular events of the WOI ER relies on the precise coordination of hormonal signaling and cellular events. During the physiological cycle, estrogen drives endometrial epithelial proliferation and angiogenesis, while progesterone facilitates functional differentiation and secretory activity, creating an optimal microenvironment for the WOI [19–22]. This transition is strictly regulated by cyclins and cyclin-dependent kinases (CDKs), which orchestrate the delicate balance between cell proliferation and apoptosis [23–26]. Concurrently, matrix metalloproteinases (MMPs) remodel the extracellular matrix (ECM), and integrins mediate crucial cell-cell interactions, establishing the structural foundation for embryo adhesion and invasion [15, 27] Immune microenvironment and ER The establishment of ER relies on endometrial remodeling and precise immune regulation (Fig. 3). During early pregnancy, the maternal immune system adapts to tolerate the semi-allogeneic embryonic cells [28]. A variety of immune cells participate in this process, including natural killer (NK) cells, macrophages, T cells, dendritic cells, and B cells, which enhance ER through cytokine secretion and direct interactions.Fig. 3Immune regulatory network in ER Immune regulatory network in ER Uterine NK cells (uNK), identified by CD56 markers, play a pivotal role: maternal uNK cells interact with fetal HLA-C ligands through killer immunoglobulin-like receptors (KIR), mediating placental-decidual interface remodeling to ensure embryonic blood supply [29]. Furthermore, uNK cells secrete cytokines such as IL-15, promoting angiogenesis and tissue remodeling [28, 30]. Beyond uNK cells, macrophages play a crucial role in immune tolerance. During embryo implantation, M1 macrophages dominate to facilitate embryo adhesion, subsequently transitioning to M2 macrophages to maintain pregnancy [31, 32]. Macrophage dysfunction may lead to implantation failure or pregnancy complications [33–35]. Treg cells prevent embryo rejection via FOXP3 expression and IL-10 secretion. CD4+ T cells and CD8+ T cells also participate in immune regulation, though their imbalance may be associated with adverse pregnancy outcomes [36–38]. Dendritic cells (DCs), as antigen-presenting cells, bridge innate and adaptive immunity. In the decidua, DCs promote tolerance by inducing Treg cell differentiation through the expression of molecules such as PD-L1 [39, 40]. Although B cells are relatively scarce in the decidua, they can produce IL-10 and PIBF1, thereby suppressing NK cell activity and inflammatory responses [41, 42]. In recent years, extracellular vesicles (EVs) have been recognized as key mediators of immune regulation. EVs carry microRNAs, proteins, and lipids released from the endometrium and embryo, modulating immune cell function. For instance, miR-138-5p in endometrial EVs influences decidual programming and placental development by regulating GPR124 and the NLRP3 inflammasome [43]. EVs can also induce monocyte differentiation and Treg cell expansion, further promoting immune tolerance [44–46]. The cytokine network finely regulates the immune microenvironment. The balance of the Th1/Th2/Th17 axis is critical: Th1 cytokines (e.g., IFN-γ, TNF-α) promote inflammation, whereas Th2 cytokines (e.g., IL-4, IL-10) support tolerance. Th17 cells secrete IL-17, which participates in trophoblast invasion, but excessive levels may lead to pathological conditions [47–49]. Cytokines such as IL-6 and IL-1β drive decidualization and trophoblast invasion [50]. Although these immune tolerance markers have advanced our understanding of pregnancy physiology, their translational potential remains challenging. uNK cell activity assays (e.g., flow cytometry) and cytokine profiling have demonstrated predictive value in research, but a lack of standardization and validation limits their routine clinical application [51, 52]. EVs, as a source of non-invasive biomarkers (e.g., from blood or uterine fluid), hold diagnostic promise, yet clinical translation requires standardized protocols for EV isolation (e.g., differentiating exosomes from larger microvesicles) and rigorous quantification platforms to minimize pre-analytical variations [44, 53, 54]. Importantly, the multi-omics cargo of these EVs—including miRNAs, proteins, and lipids—directly reflects and modulates immune-endometrial crosstalk, providing mechanistic insights into how immune cells and endometrial cells communicate at the molecular level. Therapies targeting specific immune cells (e.g., Treg cell infusion) have shown efficacy in animal models but remain in early stages of human application [36, 37]. Future research should focus on biomarker validation and the development of targeted therapies to improve reproductive outcomes. Microecological Flora and ER The uterine cavity was traditionally considered sterile; however, recent studies, particularly those utilizing high-throughput sequencing technologies, have confirmed the presence of a unique and dynamic microbial community within the uterine cavity, whose composition and balance profoundly influence the establishment of ER. A healthy endometrial microbiota is dominated by Lactobacillus. Based on the relative abundance of Lactobacillus, the uterine microbiota can be classified as Lactobacillus-dominated (LD) (Lactobacillus ≥ 90%) or non-Lactobacillus-dominated (NLD) (Lactobacillus < 90%). Multiple studies indicate a positive correlation between an LD microbiota and favorable reproductive outcomes. Moreno et al. [55] found that patients with an LD endometrial microbiota had significantly higher rates of embryo implantation, clinical pregnancy, ongoing pregnancy, and live birth compared to those with an NLD microbiota, although the taxonomic composition of the endometrial microbiota remains relatively stable in most women and is not significantly affected by hormonal changes during the WOI. Kyono et al. [56] further reported that increasing the relative abundance of Lactobacillus in the uterine microbiota to 90% significantly improved embryo implantation rates. Lactobacillus likely maintains uterine environmental homeostasis and ER through mechanisms such as competitively inhibiting pathogen colonization and modulating local cytokine levels [57, 58]. Conversely, a decrease in the proportion of Lactobacillus, leading to dysbiosis, along with the overgrowth of opportunistic pathogens (e.g., Gardnerella, Streptococcus, Prevotella), is closely associated with adverse reproductive outcomes such as CE, impaired ER [55, 59, 60]. This dysbiosis may exist independently of the vaginal microbiota status and is positively correlated with the risk of RIF. The core mechanism by which the microbiome influences ER lies in its potent immunomodulatory functions. The uterine microbiota and its metabolites continuously interact with the host immune system, modulating the activity of natural killer cells, the polarization of macrophages, and the function of regulatory T cells, collectively shaping an immune-tolerant microenvironment conducive to embryonic survival [61, 62]. Dysbiosis disrupts this immune balance, activating inflammatory pathways such as NF-κB, leading to increased levels of pro-inflammatory cytokines like IL-6 and TNF-α, which subsequently suppress the expression of key ER molecules like LIF and disrupt endometrial homeostasis [62]. Beyond the uterine microbiome, the gut microbiome also systemically influences ER via the “gut-uterus axis.” Gut dysbiosis can trigger systemic inflammation, affect estrogen metabolism and insulin sensitivity, and indirectly interfere with endometrial function [63, 64]. Studies have shown that RIF patients exhibit gut microbiota dysbiosis, and modulating the gut microbiota (e.g., by supplementing with Bifidobacterium) may help improve pregnancy outcomes [63, 64]. 16S ribosomal RNA (16S rRNA) gene analysis is a culture-independent, safe, and effective method for microbiota profiling. It reveals microbial composition and relative abundance in samples via PCR amplification and high-throughput sequencing and has been widely used in human microbiome studies [55, 56, 58]. However, when applied to female reproductive tract microbiota research, this technique faces challenges such as contamination risk due to low overall microbial biomass, and limitations in its accuracy and sensitivity [65]. Furthermore, most existing studies only reveal correlations between microbiota composition and ET outcomes, leaving the direction of causality unclear. To establish causality beyond 16S rRNA associations, future studies must utilize patient-derived endometrial organoids or microfluidic organ-on-a-chip models. These platforms can functionally validate whether specific microbial metabolites directly trigger epigenetic reprogramming or transcriptional suppression in endometrial cells. [65]. Schematic representation of immune mechanisms critical for ER. Key components include uterine natural killer cells, macrophages, cytokine signaling such as IL-10, IL-6, and IL-1β, the balance of the Th1/Th2/Th17 immune axis, and progesterone-mediated immune tolerance. Dysregulation of these pathways may impair trophoblast invasion and embryo implantation. PL: pregnancy loss, RPL: repeated pregnancy loss. Transcriptomics in ER Key mRNA profiles and their changes Current ER transcriptomics, ranging from bulk [66] to single-cell RNA-seq [67–69], has refined the identification of cell-specific contributions during the WOI. For instance, the GeneRaVE™ validated the feasibility of transcriptomic diagnosis by screening hundreds of cycle-dependent genes [66]. At the same time, the Adhesio test identified a specific gene set regulated by maternal-fetal crosstalk during the WOI [70]. Collectively, these studies have expanded our understanding of ER and identified numerous cycle-dependent mRNAs associated with ER status and pathologies such as endometriosis [71, 72]. The transcriptomic changes described above do not act in isolation; they represent an intermediate regulatory layer that bridges epigenetic priming to proteomic execution and metabolic output, integrated in section "Multi-omics Convergence on Core Biological Processes of ER". ncRNAs Regulatory role of long non-coding RNAs (lncRNAs) lncRNAs exhibit low sequence conservation and spatiotemporal specificity in the endometrium, with expression changes closely associated with endometrial remodeling and embryo implantation processes. Studies have identified specific LncRNA expression profiles in patients with RIF, such as H19, TUNAR, and PTENP1. These LncRNAs regulate processes including cell adhesion, decidualization, and immune angiogenesis through mechanisms such as competing endogenous RNA, thereby affecting ER [73–76]. However, the clinical translation faces significant challenges, including heterogeneity across different studies, questionable generalizability. Furthermore, although therapeutic strategies targeting LncRNAs (e.g., siRNA) have shown potential in animal models, their safety and clinical feasibility still require further validation. sncRNA and ER Recent studies have revealed that EVs carrying miRNAs serve as key mediators of intercellular communication and regulate ER-related pathways during endometrial-embryo crosstalk [77]. For instance, exosomal miR-30d-5p promotes endometrial decidualization via the TGF-β signaling pathway [24, 78], while exosomal miR-203a-3p improves ER by targeting SNAI1 [78]. This suggests that engineered exosomes hold promise as targeted delivery tools for endometrial repair and RIF treatment. However, challenges in scalable production, delivery efficiency, and long-term safety of engineered exosomes require resolution before clinical use. Despite extensive characterization of miRNA networks in ER (summarized in Table 1), their diagnostic performance varies dramatically, exposing key translational hurdles. For instance, one panel achieved > 90% accuracy (80% sensitivity, 100% specificity) for RIF prediction in a single study [84], while an independent EV-derived model saw its AUC plummet from 0.92 to 0.69 between its discovery and validation cohorts [85]. Most studies are limited to small, single-center cohorts, and lack the independent multi-center validation needed to ensure reproducibility. Crucially, the field suffers from a complete absence of standardized protocols across sample collection, EV isolation, and detection platforms, making cross-study comparisons unreliable [86, 87].Table 1miRNA panels for ER detection developed in recent yearsYearAuthorsSample typeCycle Phase/Definition of ReceptivityCycle Type (Natural/HRT/Stimulated)Key miRNA(s)Clinical significanceAdvantagesDisadvantagesValidation ApproachReferences2018Yanget al.Uterine FluidMid-secretory (LH + 7) vs. proliferativeNatural cyclesmiR-486-5p,miR-92b-3pRIF screening and diagnosisEasy access to uterine fluidSignificant expression fluctuationsIndependent cohort validation (n = 40)[79]2022Azhariet al.Serum Exosomes/ Endometrial TissueReceptive (LH + 6–LH+8) vs. non-receptiveNatural cycles (confirmed by hormone levels and histology)miR-661,miR-142-3p,miR-30c, etc.RIF mechanism research and diagnosisNon-invasive serum exosomes, dual validation with tissueHighly susceptible to pre-analytical variations in exosomal isolationDual validation: serum exosomes (n = 40) and endometrial tissue (n = 20)[80]2022Azhariet al.Peripheral BloodDynamic monitoring across WOI (LH + 2 to LH+9)Natural cyclesDynamicmiRNA profile (incl. miR-661, miR-142-3p)Dynamic monitoring WOINon-invasive, enables dynamic monitoringCritical dependence on sampling timepointsLongitudinal sampling within same patients (n = 15)[80]2023Segura-Benítezet al.Uterine FluidExosomesWOI (LH + 7) vs. pre-receptive (LH + 2)Natural cyclesEV-miRNAprofileEmbryo quality assessment and selectionNon-invasive sampling, enables real-time monitoringTechnically complex, lack of standardizationIn vitro functional validation (trophoblast spheroid assay)[81]2024Chen et al.SerumEarly pregnancy (days 12–14 post-ET)Stimulated IVF cyclesmiR-150-3p;miR-150-5p; miR-98-5p; miR-363-3p; miR-9-5pPrediction and monitoring of early pregnancy outcomeDynamic monitoring, non-invasiveTime-dependent, requires multiple samplingsProspective cohort validation (n = 120)[82]2025Lee et al.EndometrialTissueReceptive vs. non-receptive (classified by ERA: P + 5 in HRT cycles)HRT cycles (P + 5)miRNA-mRNA Asynchronous Expression ProfilePrecise WOI timing assessment and RIF diagnosisDual validation, predicts implantation windowClinical utility remains to be confirmed in diverse ethnic cohortsComparison with ERA outcomes (n = 85)[83] Table 1miRNA panels for ER detection developed in recent yearsYearAuthorsSample typeCycle Phase/Definition of ReceptivityCycle Type (Natural/HRT/Stimulated)Key miRNA(s)Clinical significanceAdvantagesDisadvantagesValidation ApproachReferences2018Yanget al.Uterine FluidMid-secretory (LH + 7) vs. proliferativeNatural cyclesmiR-486-5p,miR-92b-3pRIF screening and diagnosisEasy access to uterine fluidSignificant expression fluctuationsIndependent cohort validation (n = 40)[79]2022Azhariet al.Serum Exosomes/ Endometrial TissueReceptive (LH + 6–LH+8) vs. non-receptiveNatural cycles (confirmed by hormone levels and histology)miR-661,miR-142-3p,miR-30c, etc.RIF mechanism research and diagnosisNon-invasive serum exosomes, dual validation with tissueHighly susceptible to pre-analytical variations in exosomal isolationDual validation: serum exosomes (n = 40) and endometrial tissue (n = 20)[80]2022Azhariet al.Peripheral BloodDynamic monitoring across WOI (LH + 2 to LH+9)Natural cyclesDynamicmiRNA profile (incl. miR-661, miR-142-3p)Dynamic monitoring WOINon-invasive, enables dynamic monitoringCritical dependence on sampling timepointsLongitudinal sampling within same patients (n = 15)[80]2023Segura-Benítezet al.Uterine FluidExosomesWOI (LH + 7) vs. pre-receptive (LH + 2)Natural cyclesEV-miRNAprofileEmbryo quality assessment and selectionNon-invasive sampling, enables real-time monitoringTechnically complex, lack of standardizationIn vitro functional validation (trophoblast spheroid assay)[81]2024Chen et al.SerumEarly pregnancy (days 12–14 post-ET)Stimulated IVF cyclesmiR-150-3p;miR-150-5p; miR-98-5p; miR-363-3p; miR-9-5pPrediction and monitoring of early pregnancy outcomeDynamic monitoring, non-invasiveTime-dependent, requires multiple samplingsProspective cohort validation (n = 120)[82]2025Lee et al.EndometrialTissueReceptive vs. non-receptive (classified by ERA: P + 5 in HRT cycles)HRT cycles (P + 5)miRNA-mRNA Asynchronous Expression ProfilePrecise WOI timing assessment and RIF diagnosisDual validation, predicts implantation windowClinical utility remains to be confirmed in diverse ethnic cohortsComparison with ERA outcomes (n = 85)[83] miRNA panels for ER detection developed in recent years Yang et al. miR-486-5p, miR-92b-3p Azhari et al. Serum Exosomes / Endometrial Tissue miR-661, miR-142-3p, miR-30c, etc. Azhari et al. Dynamic miRNA profile (incl. miR-661, miR-142-3p) Segura-Benítez et al. Uterine Fluid Exosomes EV-miRNA profile miR-150-3p; miR-150-5p; miR-98-5p; miR-363-3p; miR-9-5p Endometrial Tissue While new computational tools like DeconmiR attempt to resolve the cellular origin of miRNAs from bulk sequencing data [88], their dependence on high-quality reference datasets means they cannot yet circumvent the fundamental need for standardized, high-quality input samples. CircRNAs are a class of ncRNAs characterized by a covalently closed circular structure. Their unique conformation confers significant resistance to exonuclease degradation, resulting in greater in vivo stability and a longer half-life. Studies have shown that, compared to fertile controls, the endometrium of patients with RIF exhibits numerous differentially expressed circRNAs, such as circ-0038383 and hsa_circ_001946. These circRNAs can regulate key genes via mechanisms like the competing endogenous RNA (ceRNA) network, thereby influencing ER [80, 89, 90]. Other small ncRNA, such as tsRNA-35:73-Asp-GTC-1, have also been reported to participate in ER regulation through the Wnt signaling pathway [91]. However, researches in this field still faces the following challenges: the regulatory network of circRNAs remains unclear, with most studies limited to single mechanisms like ceRNA; low overlap in differential expression profiles across different studies reflects reproducibility issues stemming from small sample sizes, tissue heterogeneity, and technical variations; detection methods lack standardization and large-scale clinical validation; the functional specificity and pathogenic causality of most circRNA molecules need to be must be established through targeted functional assays to prove true pathogenic causality rather than mere biological correlation. Serum small non-coding RNA (sncRNA) as non-invasive detection tools Serum sncRNAs exhibit high potential as non-invasive biomarkers for ER, especially in RIF. One study reported that a machine learning model based on serum sncRNAs expression profiles achieved an accuracy of 95.9% in internal validation and was preliminarily verified in an independent cohort using next-generation sequencing (NGS) [92]. However, this high accuracy was derived from a study with a limited sample size, and its generalizability in large-scale, multi-center populations still requires confirmation. Although serum sncRNAs testing holds considerable promise for optimizing ET timing, its clinical translation remains limited by challenges such as insufficient technical standardization, poor reproducibility, and unclear mechanisms. Crucially, these transcriptomic fluctuations do not act in isolation; they represent an intermediate regulatory layer that must be validated through proteomic execution and metabolic signaling to fully characterize the functional state of endometrial decidualization. Epigenetic biomarkers Histone modifications Histone modifications critically regulate ER by dynamically altering chromatin structure to control gene expression. During the mid-secretory phase, activating marks such as H3K27ac become enriched at promoters of key ER genes like WNT4 and ZBTB16, while repressive marks like H3K27me3 decrease, collectively promoting a transcriptional program favorable for embryo implantation [93, 94]. The transcription factor HOXA10 is also finely regulated by histone acetylation, illustrating crosstalk between transcriptional and epigenetic networks [95]. A study further showed that loss of H3K27ac downregulates progesterone receptor expression, causing abnormal luminal epithelium proliferation and impaired decidualization, thereby explaining epigenetic mechanisms behind age-related ER decline [96]. Studying histone modifications offers the advantage of revealing functional genomic regulation beyond DNA sequence, providing direct mechanistic insight into ER. However, the field faces methodological challenges: techniques like ChIP-seq and CUT&Tag are sensitive to experimental conditions such as antibody specificity and cell input [97], leading to reproducibility issues. Additionally, cellular heterogeneity in endometrial tissue may obscure cell-type-specific epigenetic events in bulk analyses [98]. As upstream regulators, these epigenetic modifications cascade down to specific transcriptomic and proteomic signatures that collectively orchestrate endometrial decidualization and immune tolerance (integrated in Sect. 8). DNA methylation DNA methylation provides a relatively stable epigenetic mechanism regulating ER. DNA methyltransferases mediate cytosine methylation to modulate gene expression, with DNMT1/3a/3b showing menstrual cycle-dependent expression in the endometrium [99]. Age-related endometrial methylation patterns serve as an epigenetic clock for biological aging, and specific aberrant profiles correlate with impaired ER in RIF patients [100]. Progesterone, acting through its nuclear receptors (PR-A and PR-B), serves as the master hormonal integrator that orchestrates these epigenetic and transcriptional changes, directly inducing HOXA10 expression and indirectly modulating LIF and integrin pathways to coordinate decidualization and immune adaptation [101]. As an ER biomarker, DNA methylation offers stable molecular insights, even enables non-invasive prediction, yet clinical use remains limited [102]. While machine learning models of cervical methylation show promise, their clinical utility requires validation in large, multi-center cohorts [103]. The role of metabolomics in ER Metabolomics provides a snapshot of the biochemical functional state by profiling small-molecule metabolites [104, 105]. In addition to lipid mediators, metabolites related to steroid and energy metabolism are emerging as potential ER biomarkers. In lipid metabolism, prostaglandins PGE₂ and PGF₂α are recognized as important markers during the WOI [106]. RIF patients exhibit downregulated endometrial expression of cPLA₂α and COX-2, impairing prostaglandin synthesis [107]. Lysophosphatidic acid (LPA) fine-tunes endometrial function via receptor LPA₃, modulating endocannabinoid and prostaglandin levels [108–110]. The endocannabinoid system, including anandamide (AEA) and 2-arachidonoylglycerol (2-AG), plays a critical role in rodent implantation, where level abnormalities cause implantation delay and reduced pregnancy rates [111]. Fatty acid amide hydrolase (FAAH), which degrades AEA, correlates with higher IVF success; low FAAH increases AEA and impairs ER [110, 112]. Polyunsaturated fatty acids also influence ER via prostaglandin, estrogen, and progesterone synthesis, and through immune and decidualization regulation [113]. These metabolic shifts are not isolated events; rather, they serve as crucial mediators that link upstream transcriptomic/epigenomic signals to the local immune microenvironment, thereby shaping maternal-fetal tolerance. Currently, endometrial fluid lipidomics is a promising approach for studying lipid-ER relationships, though current applications remain scarce and largely non-targeted [114]. Beyond lipids, metabolomic profiling also captures markers of redox homeostasis, such as reduced glutathione (GSH) and oxidized glutathione (GSSG), as well as reactive oxygen species (ROS) byproducts like 8-hydroxy-2’-deoxyguanosine (8-OHdG). Emerging evidence links an imbalance in these redox metabolites to impaired ER in conditions such as PCOS and endometriosis [115]. A major challenge is the difficulty in obtaining endometrial tissue on the day of ET, which prevents metabolic assessment at the WOI. Translating lipidomics requires validating the consistency between uterine fluid and tissue metabolism. Protein expression characteristics revealed by Proteomics Proteomic technologies have unveiled critical insights into RIF, identifying 263 differentially expressed proteins in endometrial tissues of RIF patients compared to fertile women. Notably, the downregulation of TPPP3 and HSD17B2 correlates with RIF pathogenesis, positioning them as diagnostic biomarkers and therapeutic targets [15]. Over two decades, proteomic advancements have enabled dynamic assessments of ER across menstrual cycle phases (proliferative/mid-secretory [116–120], pre-receptive/receptive [121–123]) and infertile populations (mid-secretory samples [117, 124], IVF outcomes [125]). Despite progress, most biomarkers lack validation in large cohorts. Furthermore, proteomic analysis of endometrial EVs has unveiled new research avenues. EVs are enriched with proteins such as annexin A2 and integrin αV, which facilitate embryo implantation by mediating cell adhesion and communication [126]. High-sensitivity proteomic techniques (e.g., DIA [127] and TMT labeling [128]) enable accurate profiling of minute uterine fluid samples. This methodology has been applied to whole proteome analysis of uterine fluid in frozen embryo transfer (FET) cycles. Crucially, the identification of these functional proteins directly complements transcriptomic discoveries, as the correlation between transcript and protein levels validates the central signaling cascades driving embryo adhesion. Endometrial fluid protein analysis Uterine fluid represents a valuable liquid biopsy for non-invasive evaluation of the implantation microenvironment, containing endometrial secretions, EVs, and associated proteins. Proteomic analysis directly reveals molecular signatures of ER. A FET study using TMT-LC-MS/MS identified five key differential proteins in uterine fluid [128]. Receptive phase showed elevated desmoplakin (DSP), keratin 1 (KRT1), and neuroblast differentiation-associated protein (AHNAK), while non-receptive phase exhibited increased fibulin-1 (FBLN1) and moesin (MSN). A machine learning model based on MSN and FBLN1 achieved exceptional performance (AUC = 0.98) in distinguishing receptivity status. Other proteomic investigations have revealed additional ER markers: PYGB (inflammation/glucose metabolism) is dysregulated in implantation failure patients [129]; PGR and NNMT serve as high-specificity markers in RIF patients [130]; Arginase-1 and actin-B show pregnancy-associated differences specific to uterine fluid, undetectable in serum [131]. These findings collectively demonstrate the uterine fluid proteome’s specific reflection of ER. The clinical use of proteomics is hindered by high-abundance protein interference and unstandardized collection methods [132, 133]. Additionally, supraphysiological hormone levels from ovarian stimulation alter uterine fluid proteomics, which can confound natural ER assessment [6]. Future development requires standardized workflows and multi-omics integration to enhance endometrial biological insight and advance personalized reproductive medicine [134]. Impact of pathological conditions on ER The pathological mechanisms of ER are depicted in Fig. 4, divided into three diseases: CE, Adenomyosis, and PCOS. Rather than disrupting a single molecule, these pathologies cause a “network-wide” dysregulation where abnormal epigenetic marking and transcriptomic shifts culminate in a dysfunctional metabolic and proteomic microenvironment, collectively preventing successful embryo-maternal crosstalk.Fig. 4Mechanisms of ER dysregulation in reproductive diseases. The upper panel summarizes four shared pathogenic mechanisms: inflammatory imbalance (driven by TNF-α and NF-κB activation, promoting pro-inflammatory factor release), microbial dysbiosis (characterized by reduced Lactobacillus and pathogenic overgrowth, exacerbating local inflammation), ECM remodeling abnormalities (MMPs/TIMPs imbalance destabilizing extracellular matrix structure and downregulating adhesion molecules), and hormonal dysregulation (impaired PGR and ESR signaling). The lower panel compares disease-specific mechanisms and therapies across three reproductive disorders: CE features JAK/STAT pathway overactivation; adenomyosis involves HOXA10 methylation defects, disrupted LEF1-IL-11 signaling, and PI3K/AKT pathway overactivation; PCOS highlights metabolic-oxidative stress (e.g., mitochondrial ROS burst, insulin resistance) and gut microbiota imbalance (Firmicutes/Bacteroidetes ratio disruption). The figure employs dynamic symbols (↑/↓ arrows, lightning bolts) to visualize molecular interactions Mechanisms of ER dysregulation in reproductive diseases. The upper panel summarizes four shared pathogenic mechanisms: inflammatory imbalance (driven by TNF-α and NF-κB activation, promoting pro-inflammatory factor release), microbial dysbiosis (characterized by reduced Lactobacillus and pathogenic overgrowth, exacerbating local inflammation), ECM remodeling abnormalities (MMPs/TIMPs imbalance destabilizing extracellular matrix structure and downregulating adhesion molecules), and hormonal dysregulation (impaired PGR and ESR signaling). The lower panel compares disease-specific mechanisms and therapies across three reproductive disorders: CE features JAK/STAT pathway overactivation; adenomyosis involves HOXA10 methylation defects, disrupted LEF1-IL-11 signaling, and PI3K/AKT pathway overactivation; PCOS highlights metabolic-oxidative stress (e.g., mitochondrial ROS burst, insulin resistance) and gut microbiota imbalance (Firmicutes/Bacteroidetes ratio disruption). The figure employs dynamic symbols (↑/↓ arrows, lightning bolts) to visualize molecular interactions Chronic endometritis CE disrupts endometrial immune homeostasis through an imbalance of pro-inflammatory factors such as IL-6 and TNF-α and anti-inflammatory mediators like IL-10, compromising the local microenvironment [135–137]. Increased infiltration of plasma cells and macrophages, impaired regulatory T cell function, and reduced NK cell activity diminish immune tolerance at the embryo-maternal interface [138, 139]. It exacerbates cell proliferation-apoptosis imbalance via JAK/STAT signaling, further impairing ER [140, 141]. In CE, leptin overexpression activates JAK/STAT and NF-κB pathways, promoting inflammatory mediator release and disrupting endometrial cell proliferation and angiogenesis [136, 142]. Concurrently, pathogenic bacteria replace Lactobacillus dominance in the endometrial microbiome, perpetuating inflammation via superoxide/IL-6 release [143]. This microbial shift directly inhibits embryo adhesion and endometrial repair [26, 144]. Abnormal ECM remodeling in CE manifests as MMPs/TIMPs imbalance and reduced E-cadherin and integrin expression, destabilizing endometrial architecture and weakening embryo adhesion [135]. While traditional antibiotic therapy alleviates inflammation, risks of antibiotic resistance and microbiome disruption limit its efficacy [140, 143]. Novel strategies like probiotics [144, 145], PRP therapy [144], and leptin/NF-κB inhibitors [142, 146] show promise for restoring ER. Future integration of molecular biomarker profiling and personalized therapies is critical to optimizing fertility outcomes. Adenomyosis Adenomyosis markedly reduces ER via multi-level molecular mechanisms, impairing embryo implantation and pregnancy outcomes. Research shows that adenomyosis patients exhibit significant transcriptomic abnormalities in the endometrium during the WOI, including activation of interferon and TNF pathways and accumulation of 909 DEGs. These changes worsen inflammation and endometrial dysfunction [147–149]. Critical transcription factors like HOXA10 and LEF1 are downregulated, suppressing decidualization. Epigenetic alterations in HOXA10, particularly PRMT5-mediated methylation abnormalities, and dysregulation of the LEF1-IL-11 signaling axis, directly impair ER [150]. Immune imbalance, marked by reduced NK cells, impaired macrophages, and excess inflammatory cytokines, such as TNF-α and IL-6, amplifies the inflammatory environment and disrupts embryo tolerance via NF-κB/MAPK pathways [138, 148]. Abnormal ECM remodeling and hormonal receptor dysfunction also reduce ER. Imbalances in ECM composition, such as abnormal collagen I/III ratios, combined with elevated MMP activity, reduce critical adhesion molecules like β3-integrin, thereby impairing embryo-endometrial interaction [149, 151–153]. Reduced PGR and ESR expression or dysfunction cause progesterone resistance and estrogen signaling imbalance, disrupting decidualization and hormone-immune coordination [148, 154–156]. Animal models link aberrant PI3K/Akt, MAPK, and TNF pathway activation to adenomyosis features like myometrial damage and inflammation [157, 158]. While therapies like GnRH agonists modulate immune activity, the limited success of implementing personalized embryo transfer (pET) highlights the need for molecular therapies targeting HOXA10, LEF1/IL-11, and related pathways. Future studies should combine multi-omics and endometrial organoids to pinpoint therapeutic targets. Polycystic ovary syndrome During the WOI, PCOS disrupts ER via oxidative stress imbalance, marked by elevated ROS levels and deficient antioxidant enzymes like superoxide dismutase. These changes drive apoptosis, suppress proliferation, and reduce E-cadherin expression, impairing endometrial integrity. Insulin resistance and lipid metabolism disorders worsen oxidative stress and inflammation by disrupting glucose and fatty acid homeostasis, compromising ER [159, 160]. Chronic low-grade inflammation in the PCOS endometrium activates the NF-κB/MAPK pathways through TNF-α and IL-6, inhibits decidualization, and disrupts immune cell balance, worsening the microenvironment [161]. Hyperandrogenemia and estrogen/progesterone imbalance suppress endometrial proliferation, induce insulin resistance, and disrupt ESR/PGR receptor expression, reducing hormonal sensitivity [162, 163]. Furthermore, vascular dysfunction, such as decreased VEGF, and structural abnormalities like glandular hypoplasia, further limit endometrial thickness and nutrient supply, hindering implantation [164]. With reduced SCFA-producing bacteria and increased pro-inflammatory taxa, gut microbiota dysbiosis amplifies systemic inflammation and metabolic disturbances [165–167]. Current therapies, including metformin, an insulin sensitizer, antioxidants, and GnRH agonists, partially restore endometrial function but show limited efficacy [70, 168, 169]. Novel strategies targeting HOXA10, inflammatory pathways, and microbiota modulation are necessary. Multi-omics and single-cell analyses hold promise for uncovering molecular networks and advancing precision treatments. Commercially available tests Commercial microbiome analysis kits represent one of the most clinically advanced applications in ER multi-omics research. Among these, EMMA® (Endometrial Microbiome Metagenomic Analysis) and ALICE® (Analysis of Infectious Chronic Endometritis), two commercial tests assessing the endometrial microenvironment, are often integrated with ERA using the same biopsy sample. EMMA evaluates microbial composition via 16S rRNA sequencing, establishing > 90% Lactobacillus as ideal for implantation and recommending probiotics for abnormal cases [170]. ALICE detects CE pathogens missed by histology, with targeted antibiotics improving outcomes [171]. Transcriptomics tools are also emerging clinically. ERA analyzes 238 genes for WOI prediction [172], though a 2022 real-world study showed no live birth improvement in general IVF populations, limiting its potential value to selected RIF cases [173]. This concept has been extended to other transcriptomic platforms, such as the ER Map/ER Peak, WIN-TEST, rsERT, and BeREady [174–180]. However, despite their technical diversity, these tools (summarized in Table 2) share common translational challenges: most lack validation from large, independent RCTs, have not yet been proven cost-effective, and their clinical value seems limited to a specific subset of RIF patients rather than the general IVF population [170, 171]. Therefore, their routine use cannot be universally recommended without further evidence.Table 2Characteristics of newer methods and kits for detecting ER transcriptomeName of theassays or kitsMarkersMethodSensitivitySpecificityValidated PopulationsCycle Types ValidatedAdvantagesDisadvantagesWindow of Implantation Test(WIN-TEST)5 genes (MFAP5, ANGPTL1, PROK1, NLF2, LAMB3, BCL2L10, CD68, TRPC4, SORCS1, FST, and KRT80)Quantitative RT-PCR,DNA chip, Protein measurement--RIF patients, general IVF populationNatural cycles (LH + 5 to LH+9), HRT cycles (P + 5 to P + 9)Ease ofperformance,standardization, minimal variationInsufficient prospective evidence from non-industry-funded multi-center trialsEndometrial Receptivity Array(ERA)238 genesMicroarraytechnology90%97%RIF patients, oocyte donors, general IVF populationNatural cycles (LH + 7), HRT cycles (P + 5)Standardized,independent of user/lot/site,reliable results in 2–3 weeksLow predictive value in unselected IVF populations; results vary by cycle typeER Map16 genesRT-PCR100%(initial findings)100%(initial findings)General IVF population, RIF patientsNatural and HRT cyclesHigh accuracy,similar biopsy and shipment as ERAHigh accuracy,similar biopsy and shipment as ERAER Peak40 genesRT-PCR--RIF patientsNatural and HRT cyclesPromising pregnancyand live birth rates in RIFMinimal data on live birth rate (LBR) improvement in randomized controlled trialsBeREady67 genesTAC-seq75%100%RIF patients, general IVF populationNatural and HRT cycles; validated in uterine fluid EVsMinimally invasive,high specificityLower sensitivityrsERT175 genesRNAsequencing98.4% (cross-validation)-RIF patients, PGT cyclesNatural and HRT cyclesHigh accuracy (98.4%),effective in diagnosing WOI, improves pregnancy success ratesSmall discovery cohort (n = 175); clinical robustness across different labs is unproven Table 2Characteristics of newer methods and kits for detecting ER transcriptomeName of theassays or kitsMarkersMethodSensitivitySpecificityValidated PopulationsCycle Types ValidatedAdvantagesDisadvantagesWindow of Implantation Test(WIN-TEST)5 genes (MFAP5, ANGPTL1, PROK1, NLF2, LAMB3, BCL2L10, CD68, TRPC4, SORCS1, FST, and KRT80)Quantitative RT-PCR,DNA chip, Protein measurement--RIF patients, general IVF populationNatural cycles (LH + 5 to LH+9), HRT cycles (P + 5 to P + 9)Ease ofperformance,standardization, minimal variationInsufficient prospective evidence from non-industry-funded multi-center trialsEndometrial Receptivity Array(ERA)238 genesMicroarraytechnology90%97%RIF patients, oocyte donors, general IVF populationNatural cycles (LH + 7), HRT cycles (P + 5)Standardized,independent of user/lot/site,reliable results in 2–3 weeksLow predictive value in unselected IVF populations; results vary by cycle typeER Map16 genesRT-PCR100%(initial findings)100%(initial findings)General IVF population, RIF patientsNatural and HRT cyclesHigh accuracy,similar biopsy and shipment as ERAHigh accuracy,similar biopsy and shipment as ERAER Peak40 genesRT-PCR--RIF patientsNatural and HRT cyclesPromising pregnancyand live birth rates in RIFMinimal data on live birth rate (LBR) improvement in randomized controlled trialsBeREady67 genesTAC-seq75%100%RIF patients, general IVF populationNatural and HRT cycles; validated in uterine fluid EVsMinimally invasive,high specificityLower sensitivityrsERT175 genesRNAsequencing98.4% (cross-validation)-RIF patients, PGT cyclesNatural and HRT cyclesHigh accuracy (98.4%),effective in diagnosing WOI, improves pregnancy success ratesSmall discovery cohort (n = 175); clinical robustness across different labs is unproven Characteristics of newer methods and kits for detecting ER transcriptome Window of Implantation Test (WIN-TEST) Quantitative RT-PCR, DNA chip, Protein measurement Ease of performance, standardization, minimal variation Endometrial Receptivity Array (ERA) Microarray technology Standardized, independent of user/lot/site, reliable results in 2–3 weeks 100% (initial findings) 100% (initial findings) High accuracy, similar biopsy and shipment as ERA High accuracy, similar biopsy and shipment as ERA Promising pregnancy and live birth rates in RIF Minimally invasive, high specificity RNA sequencing High accuracy (98.4%), effective in diagnosing WOI, improves pregnancy success rates Multi-omics convergence on core biological processes of ER Although multi-omics studies ER has generated vast parallel datasets, true integration requires demonstrating how distinct molecular layers converge on the same biological endpoints. Each omics layer carries distinct advantages and translational hurdles (Table 3). Rather than treating transcriptomics, proteomics, metabolomics, epigenetics, microbiomics, and exosomes as independent discovery pipelines, we reframe ER as an integrated network in which these layers collectively regulate three critical processes that define the WOI: (1) endometrial decidualization, (2) immune tolerance, and (3) embryo adhesion with structural remodeling (Fig. 5).Table 3Comparative analysis of multi-omics in ER researchOmics layerKey technologiesCore advantagesCore disadvantagesPrimary translational hurdleTranscriptomicsMicroarray, RNA-seq, scRNA-seqCaptures dynamic gene expression; high commercial maturity.RNA instability; high inter-individual variability.Lack of robust, multi-center clinical validation for commercial tests.ProteomicsLC-MS/MS, TMT,DIADirectly reflects functional protein activity and pathways.Susceptible to pre-analytical variability; complex data.Standardization of sample processing and analytical workflows.MetabolomicsLC-MS, lipidomicsProvides a real-time snapshot of biochemical functional state.Highly sensitive to environmental and dietary confounders.Underdeveloped for ER; difficulty in capturing the precise WOI.EpigenomicsChIP-seq, DNA methylation arraysReveals stable, mechanistic regulatory insights beyond genetics.Technically complex; results difficult to reproduce across labs.High technical complexity and lack of standardized clinical protocols.Microbiomics16S rRNA sequencingDefines the microenvironment with clear, actionable interventions.Challenging to establish causality from correlation.Risk of sample contamination and establishing definitive causality.ExosomesUltracentrifugation, NTA, omics analysisIntegrates multi-omics signals from a stable, non-invasive source.Isolation methods are not standardized; biological heterogeneity.Lack of standardized isolation methods and understanding of heterogeneity.Fig. 5Multi-omics profiling of ER biomarkers across different biological compartments. Biomarkers are identified from three biological compartments: endometrial fluid, endometrial tissue, and serum. Multi-omics analyses are performed, including proteome (blue) - comprehensive protein profiling; transcriptome (yellow) - gene expression analysis; Epigenome (green) - epigenetic modifications; and ncRNAs (pink) - regulatory RNA molecules. This integrated approach enables the identification of molecular signatures associated with impaired ER across different sample types Table 3Comparative analysis of multi-omics in ER researchOmics layerKey technologiesCore advantagesCore disadvantagesPrimary translational hurdleTranscriptomicsMicroarray, RNA-seq, scRNA-seqCaptures dynamic gene expression; high commercial maturity.RNA instability; high inter-individual variability.Lack of robust, multi-center clinical validation for commercial tests.ProteomicsLC-MS/MS, TMT,DIADirectly reflects functional protein activity and pathways.Susceptible to pre-analytical variability; complex data.Standardization of sample processing and analytical workflows.MetabolomicsLC-MS, lipidomicsProvides a real-time snapshot of biochemical functional state.Highly sensitive to environmental and dietary confounders.Underdeveloped for ER; difficulty in capturing the precise WOI.EpigenomicsChIP-seq, DNA methylation arraysReveals stable, mechanistic regulatory insights beyond genetics.Technically complex; results difficult to reproduce across labs.High technical complexity and lack of standardized clinical protocols.Microbiomics16S rRNA sequencingDefines the microenvironment with clear, actionable interventions.Challenging to establish causality from correlation.Risk of sample contamination and establishing definitive causality.ExosomesUltracentrifugation, NTA, omics analysisIntegrates multi-omics signals from a stable, non-invasive source.Isolation methods are not standardized; biological heterogeneity.Lack of standardized isolation methods and understanding of heterogeneity. Comparative analysis of multi-omics in ER research LC-MS/MS, TMT, DIA Multi-omics profiling of ER biomarkers across different biological compartments. Biomarkers are identified from three biological compartments: endometrial fluid, endometrial tissue, and serum. Multi-omics analyses are performed, including proteome (blue) - comprehensive protein profiling; transcriptome (yellow) - gene expression analysis; Epigenome (green) - epigenetic modifications; and ncRNAs (pink) - regulatory RNA molecules. This integrated approach enables the identification of molecular signatures associated with impaired ER across different sample types Multi-omics convergence on endometrial Decidualization Decidualization is primarily driven by transcriptome–epigenome crosstalk that fine-tunes master transcription factors. HOXA10 exemplifies this integration: its expression is concurrently regulated by hormonal signals, histone acetylation (H3K27ac enrichment during mid-secretory phase), and DNA methylation (age-related hypermethylation in RIF patients) [93, 94, 100]. At the proteomic level, PCAF acetylates the HOXA10 protein, repressing its target ITGB3 and impairing ER [95]. This epigenome–transcriptome cascade ultimately drives a metabolic reprogramming reflected in the metabolome: altered synthesis of lipid mediators such as PGE₂ and PGF₂α serves as essential downstream functional signals for decidualization and tissue remodeling [106, 107]. Thus, decidualization represents a convergence node where epigenetic priming, transcriptional activation, and metabolic execution are sequentially linked. Multi-omics regulation of the receptive immune microenvironment A receptive endometrium requires precise immune modulation, achieved through convergence of multiple regulatory layers. First, DNA methylation changes directly correlate with dysregulation of inflammatory proteins: hypomethylation of SERPINA5 and NLRP2 promoters in RIF cases activates inflammatory cascades [181]. Second, exosomal miRNAs (e.g., miR-30d-5p, miR-203a-3p) bridge intercellular communication to mediate macrophage polarization and maternal–fetal tolerance [24, 77, 78]. Third, the endometrial microbiome shapes this network: dysbiosis (reduced Lactobacillus dominance) alters metabolic outputs and disrupts the Th1/Th2 cytokine balance via NF-κB activation and IL-6/TNF-α elevation [47–49, 62]. Therefore, immune tolerance is jointly determined by epigenetic priming, exosomal RNA transfer, and microbial–host metabolic crosstalk—not by any single omics layer. Integrated networks for embryo adhesion and tissue remodeling Physical embryo adhesion relies on a signaling hub where transcriptomic, non-coding RNA, and proteomic data functionally converge. Transcriptome-identified markers (LIF, ITGB3, HOXA10) show reduced expression in RIF, which is validated by independent proteomic profiling [182], confirming that the LIF‑JAK/STAT, HOXA10‑Wnt/β‑catenin, and integrin‑mediated adhesion cascades operate as central integrators. The ncRNA layer adds regulatory complexity: miR-145 targets IGF1R and HOXA10 mRNAs to inhibit translation [181, 183], while lncRNA H19 acts as a ceRNA for let‑7, indirectly modulating ITGB3 protein and embryo adhesion [74, 184]. Furthermore, untargeted proteomics confirms that structural and metabolic proteins (TPPP3, HSD17B2) decrease in RIF, directly supporting functional tissue remodeling [15]. Hence, adhesion competence emerges from coordinated mRNA–ncRNA–protein networks, with each layer providing non‑redundant regulatory control. Collectively, the above convergence mapping demonstrates that ER is not the sum of independent transcriptomic, proteomic, or metabolomic signatures. Instead, each core biological process integrates inputs from multiple omics layers: (i) decidualization sequentially integrates epigenomic, transcriptomic, and metabolomic signals; (ii) immune tolerance integrates epigenetic regulation, exosomal RNA transfer, and microbiome–metabolite crosstalk; (iii) embryo adhesion integrates mRNA, ncRNA, and proteomic execution. This framework moves beyond “multi-omics as parallel description” toward mechanistically grounded integration, providing a rational basis for selecting biomarker panels that reflect convergent pathway activity rather than isolated molecular hits. Research challenges and evidence gaps Technical challenges: standardization and reproducibility Integrating multi-omics biomarkers into ART workflows remains challenging due to practical and analytical bottlenecks. Sample processing and inter-platform variability Each step from sample collection to data generation can introduce significant variability. Since ER status is hormone-sensitive, patient characteristics such as age, BMI, and inflammatory status can confound biomarker studies, as they independently influence endometrial gene expression and ER. These clinical parameters must be systematically recorded for batch-effect correction. For instance, advanced maternal age alters DNA methylation [100] and epigenetic marks like H3K27ac [96]; elevated BMI is linked to chronic inflammation and transcriptomic changes [160]. In the reviewed studies, adjustment for these confounders varied: some used multivariate regression or propensity score matching [82, 83], while others relied on group matching only; few assessed inflammatory status. This heterogeneity limits cross-study comparability and underscores the need for systematic collection and adjustment of key variables in future studies. To enhance transparency, Table 1 now indicates which studies reported confounder adjustment. During sample preprocessing, subtle variations—including tissue freezing temperature, cell dissociation enzyme lot, and RNA stabilizer type—can significantly affect transcriptomic results. The Quartet Project revealed that switching commercial RNA extraction kits alone introduced over 20% batch effects, increasing false discovery rates of differential genes [185]. In proteomics, a cross-laboratory study with 21 labs across 11 countries reported a median coefficient of variation (CV) of 18.7% in protein quantification of the same endometrial tissue using DIA-SWATH. However, after adopting standardized protocols with isotope-labeled internal standards, the CV decreased to 7.4%, highlighting the value of standardization and internal calibration for reducing technical noise [186]. Platform differences further amplify variability. Sequencing identical metagenomic libraries on Illumina NextSeq and BGI DNPSEQ systems led to a 34% difference in α-diversity indices, with 12% of Operations Taxonomic Unit (OTUs) showing platform-specific detection [187]. In metabolomics, only 62% of lipid peaks matched across LC-QTOF and LC-Orbitrap platforms for the same serum sample, and quantitative ranges varied by 2–3 orders of magnitude, complicating feature selection for machine learning [188]. Fragmented bioinformatics and poor model generalization Variability in bioinformatics pipelines is another major concern. Reproducibility analysis of 35 ER transcriptomic studies showed that software updates (e.g., HISAT2 or edgeR) reduced overlap in reported differential genes from 78% to 53% [189]. In machine learning, poor generalization remains common. High-dimensional omics data, where the number of features far exceeds the number of samples, makes models particularly prone to overfitting. Many current studies rely only on internal cross-validation and lack independent external validation, which directly contributes to poor model generalizability. AI models trained on single-center data often perform poorly externally, with cross-center accuracy dropping by 0.21 units on average [190]. Key reasons include technical and biological variations across sites and inconsistent handling of class imbalance, limiting model adaptability. For multi-omics to accurately assess ER, three issues must be resolved: inaccurate detection, incomparable data, and limited clinical utility. This requires certified reference materials, unified SOPs, reproducible computational workflows, and rigorous validation. Critical appraisal of Current evidence Despite the promise of multi-omics, the overall quality of evidence supporting clinical translation remains modest. First, most discovery studies are conducted in small pilot cohorts (often n < 30), increasing the risk of overfitting and limiting generalizability [85, 126]. Second, methodological heterogeneity—particularly in sampling timing (e.g., LH + 7 vs. P + 5) and collection techniques (biopsy vs. uterine fluid)—severely undermines cross-study comparability [133]. Third, the vast majority of reported biomarkers remain associative rather than causative; few studies employ functional models such as endometrial organoids to establish mechanistic links between candidate molecules and implantation outcomes [65]. Finally, independent replication by non-industry-funded groups is sparse, raising concerns about the reproducibility of commercially promoted panels. Addressing these limitations will require multi-center biobanks with standardized protocols, consensus reporting guidelines, and mandatory external validation before clinical deployment [185, 189]. Clinical integration and practical hurdles The clinical utility of multi-omics biomarkers depends on their seamless integration into existing IVF workflows. Currently, commercial tools like ERA typically require an invasive endometrial biopsy during a “mock” cycle, which increases the financial burden and delays embryo transfer. Multi-omics approaches, particularly those utilizing uterine fluid, offer the potential for a “liquid biopsy” that could be performed during the actual transfer cycle, providing a real-time assessment of endometrial readiness. In the current landscape, these multidimensional biomarkers are poised to complement existing transcriptomic tests by identifying immune or metabolic dysregulation in patients who appear “receptive” on a transcriptome level but still experience implantation failure. As non-invasive models achieve greater validation, they may eventually replace biopsy-based methods. However, significant barriers to implementation remain: (i) High Cost: The operational expense of combined sequencing and mass spectrometry currently exceeds single-platform assays; (ii) Turnaround Time (TAT): Multi-omics data processing must be accelerated to fit within the narrow temporal window of an ART cycle; and (iii) Clinical Validation: demonstrating cost-effectiveness and superiority over standard care requires large-scale RCTs, which are resource-intensive and currently lacking for most multi-omics panels. Translational roadmap: from biomarker to clinic While multi-omics has exponentially expanded ER biomarker candidates, fewer than 1–2 per year achieve regulatory approval and enter routine IVF practice. To address this gap, we integrate guidelines from the NIH, FDA, EMA, and EDRN into a six-stage translational framework (6-STR) for ER multi-omics biomarkers (Table 4). The 6-STR framework is also applicable to other reproductive conditions, such as embryo selection and pre-eclampsia.Table 4Six-stage translational roadmap (6-STR) for ER multi-omics biomarkersStageKey questionRecommended technology/study designSuccess metricCommon pitfall① DiscoveryWhich molecules correlate most tightly with WOI?Time-course single-cell RNA-seq + proteomics + metabolomics [191]; machine-learning feature selectionAUC-ROC ≥ 0.8 in an independent set (n ≥ 60)Batch effects, cohort heterogeneity② Identification/CharacterizationMolecular form, post-translational modifications, in-vivo half-life?Mass spectrometry multiple reaction monitoring (MRM), glycosylation/phosphorylation site localization“Locked-down” assay prototype establishedIgnoring isoform heterogeneity③ Analytical ValidationIs the assay accurate, reproducible and platform-agnostic?Follow CLSI EP15/EP17; multi-centre interchangeability study [192]CV < 10%, recovery 85–115%, LoD/LoQ metLack of standardized collection/thaw cycles④ Clinical ValidationDoes the biomarker predict implantation outcome?Prospective, multi-centre, nested case–control (n ≥ 500 cycles) [193]Sensitivity > 0.9, specificity > 0.8, NPV > 0.95Single-centre bias, population stratification⑤ Clinical Utility & RegulatoryDoes it improve decision-making and is it cost-effective?RCT: “biomarker-guide” vs “morphology-only” transfer; budget-impact analysisImplantation rate ↑ ≥15%, ICER < $ 30 000/QALY; FDA/CE approval [194]Payer access, weak IP portfolio⑥ ImplementationHow is it deployed in a routine IVF laboratory?SOP automation, AI read-out plug-in, staff training, guideline inclusion≥80% uptake within 12 months, TAT < 24 h, patient satisfaction > 90%Absence of continuous QC, data silos Table 4Six-stage translational roadmap (6-STR) for ER multi-omics biomarkersStageKey questionRecommended technology/study designSuccess metricCommon pitfall① DiscoveryWhich molecules correlate most tightly with WOI?Time-course single-cell RNA-seq + proteomics + metabolomics [191]; machine-learning feature selectionAUC-ROC ≥ 0.8 in an independent set (n ≥ 60)Batch effects, cohort heterogeneity② Identification/CharacterizationMolecular form, post-translational modifications, in-vivo half-life?Mass spectrometry multiple reaction monitoring (MRM), glycosylation/phosphorylation site localization“Locked-down” assay prototype establishedIgnoring isoform heterogeneity③ Analytical ValidationIs the assay accurate, reproducible and platform-agnostic?Follow CLSI EP15/EP17; multi-centre interchangeability study [192]CV < 10%, recovery 85–115%, LoD/LoQ metLack of standardized collection/thaw cycles④ Clinical ValidationDoes the biomarker predict implantation outcome?Prospective, multi-centre, nested case–control (n ≥ 500 cycles) [193]Sensitivity > 0.9, specificity > 0.8, NPV > 0.95Single-centre bias, population stratification⑤ Clinical Utility & RegulatoryDoes it improve decision-making and is it cost-effective?RCT: “biomarker-guide” vs “morphology-only” transfer; budget-impact analysisImplantation rate ↑ ≥15%, ICER < $ 30 000/QALY; FDA/CE approval [194]Payer access, weak IP portfolio⑥ ImplementationHow is it deployed in a routine IVF laboratory?SOP automation, AI read-out plug-in, staff training, guideline inclusion≥80% uptake within 12 months, TAT < 24 h, patient satisfaction > 90%Absence of continuous QC, data silos Six-stage translational roadmap (6-STR) for ER multi-omics biomarkers Conclusion and prospects By shifting toward a systems biology approach, multi-omics integration has successfully resolved the dynamic landscape of ER across tissue and non-invasive compartments (e.g., uterine fluid). However, translating these mechanistic signatures into robust clinical platforms like ERA or EMMA/ALICE remains hindered by analytical bottlenecks and a lack of standardized validation protocols. While many biomarkers show promise, their efficacy in improving live birth rates remains unconfirmed in large-scale prospective trials. To bridge this gap, future research must prioritize statistical rigor—including standardized multiple testing corrections and robust power calculations—to ensure reproducibility. Finally, the deployment of interdisciplinary AI-driven models and comprehensive cost-effectiveness analyses will be pivotal in establishing personalized embryo transfer as a global standard for infertility management.